News Regeneron tries again with lymphoma bispecific in US Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.
News Can Keytruda finally break into early head and neck cancer? The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.
News Perlmutter's Eikon raises $351m in major financing round Eikon has added to its already copious cash reserves with a $351m round for its expanding pipeline of cancer therapies.
News Data cues up AZ oral SERD filing in first-line breast cancer AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.
News Rishi Sunak becomes prostate cancer ambassador Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador for its campaign for a national screening programme.
News FDA looks at Opdivo/Yervoy in first-line colorectal cancer The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.